Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 15th 2017

Real-World Data Used to Inform Approval of Low-Dose Cabazitaxel for Prostate Cancer

Surabhi Dangi-Garimella, PhD

Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.

September 15th 2017

Copanlisib Receives Accelerated Approval for Relapsed Follicular Lymphoma

Christina Mattina

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

September 14th 2017

First Anticancer Biosimilar Treatment Approved for Multiple Indications

Surabhi Dangi-Garimella, PhD

The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.

September 14th 2017

Representatives Probe CMS for Further Detail on New CAR-T Therapy Payment Agreement

Christina Mattina

After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement.

September 13th 2017

FDA Announces Progress, Next Steps in Streamlining Orphan Drug Review Process

Christina Mattina

FDA Commissioner Scott Gottlieb, MD, announced the agency’s progress in streamlining the orphan drug review process and outlined plans to close a loophole currently hindering pediatric drug research.

September 12th 2017

Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds

Christina Mattina

How much does it cost for a drug maker to develop a new drug? Prior estimates have put this figure as high as $2.7 billion, but a new study indicates that the median cost of development for 10 cancer drugs was actually $648 million-a substantial discrepancy.

September 12th 2017

MACRA Survey Finds Oncology Physicians Unprepared for Payment Changes

Surabhi Dangi-Garimella, PhD

A recent survey conducted by Integra Connect has found that a majority of specialty physicians have not yet invested in operational changes that may be essential for their success under value-based care reimbursement models.

September 12th 2017

ASCO Releases Guidelines on Patient—Clinician Communication

Christina Mattina

The American Society of Clinical Oncology (ASCO) has published a set of guidelines and best practices that can help clinicians improve how they communicate with patients receiving cancer therapy and their families.

September 11th 2017

The American Journal of Managed Care® Presents the Advanced Payment Models in Oncology Webcast Series

This webcast will discuss the Oncology Care Model from the perspective of a clinician and a payer.

September 11th 2017

ESMO 2017: Nivolumab-Ipilimumab Combination Reduced Risk of Death in RCC by 37%

Surabhi Dangi-Garimella, PhD

CheckMate-214 results presented at the European Society of Medical Oncology meeting show improved overall survival in patients with renal cell carcinoma treated with the nivolumab-ipilimumab combination, compared with sunitinib.

September 10th 2017

Dr Lee Newcomer on Policy Decisions as New Immunotherapy Agents Are Developed

Lee N. Newcomer, MD, MHA, senior vice president of oncology and genetics at UnitedHealthcare, discusses off-label communications and how coverage determinations are changing along with the production of new immunotherapy agents.

September 10th 2017

Geographic Gaps in BRCA Testing Rates Have Narrowed

Christina Mattina

In recent years, testing for the BRCA1/2 gene mutations has increased among women in both metropolitan and nonmetropolitan areas, helping to drastically reduce the gap in testing rates between the groups.

September 9th 2017

Podcast: This Week in Managed Care - ACA Stabilization Proposals, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 8th 2017

Cost Conversations in Oncology Care Led to Alternate Cost-Reducing Interventions

Surabhi Dangi-Garimella, PhD

Oncologist- as well as patient-initiated conversations on the cost of cancer care led to conversations on cost-reducing strategies 38% of the time, according to a new study published in the Journal of Oncology Practice.

September 8th 2017

This Week in Managed Care: September 8, 2017

This week, the top managed care stories included more insurers rolling back participation in Affordable Care Act exchanges, while governors testify ways to stabilize the market; the FDA put 3 combination trials of nivolumab on hold; and a study finds very few visits to the emergency department are truly avoidable.

September 8th 2017

Researchers Develop Pen Tool for Quickly Identifying Cancer Tissue During Surgery

Christina Mattina

“Is the pen mightier than the scalpel?” A new study aims to answer that question by presenting research on a handheld pen-sized device that can rapidly determine cancer tissue borders during surgery.

September 7th 2017

Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused

Surabhi Dangi-Garimella, PhD

Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

September 6th 2017

Using Patient-Reported Distress to Guide the Timing of Palliative Care Conversations

Christina Mattina

After presenting research on the use of a patient-reported distress survey to guide the timing of palliative care discussions, lead author Stuart Goldberg, MD, chief scientific officer for Cota, Inc, discussed how it represents a shift in the paradigm of end-of-life conversations.

September 6th 2017

ctDNA Plus Protein Biomarker Test Allows Early Detection of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

A single blood draw that combines the detection of DNA and protein markers could be more sensitive to the earlier detection of pancreatic cancer, according to a new study published in Proceedings of the National Academy of Sciences.

September 5th 2017

Companies Continue to Face Challenges With Developing CAR-T Treatment

Surabhi Dangi-Garimella, PhD

Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.

September 5th 2017

Mammography Device Approved by FDA Gives Patients Control Over Pressure Levels

Christina Mattina

The FDA has approved the first 2D digital mammography system that lets patients adjust the level of compression applied to their breast during the imaging procedure.

September 4th 2017

Consistent Use of E-Cigarettes Can Help Smoking Cessation

AJMC Staff

According to a study published in The BMJ, while e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

September 4th 2017

Dr Kashyap Patel Discusses Implementing the Oncology Care Model

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, explains how previous experience with alternative payment models helped a smooth transition into the Oncology Care Model (OCM).

September 3rd 2017

Podcast: This Week in Managed Care - Hurricane Relief Efforts, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

AJMC Staff

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

September 1st 2017

Dr Charlie Fazio on Balancing Different Delivery and Payment Models

Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses how to balance different payment models in order to understand their impacts on cost and patient outcomes when they are implemented.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

September 1st 2017

This Week in Managed Care: September 1, 2017

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.

September 1st 2017

FDA Emphasizes Risks of Pembrolizumab in Multiple Myeloma After Reviewing Halted Trials

Christina Mattina

Less than 2 months after it ordered a stop to 3 trials of pembrolizumab (Keytruda) in multiple myeloma due to safety concerns, the FDA has released a more detailed analysis of what went wrong in these trials.

...

66 67 68 69 70 71 72 73 74

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions